The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas. [electronic resource]
Producer: 20151106Description: 537-45 p. digitalISSN:- 1473-4877
- Age Factors
- Antineoplastic Agents -- therapeutic use
- Brentuximab Vedotin
- Disease Management
- Disease Progression
- Hodgkin Disease -- epidemiology
- Humans
- Immunoconjugates -- therapeutic use
- Ki-1 Antigen -- metabolism
- Lymphoma, Large-Cell, Anaplastic -- epidemiology
- Molecular Targeted Therapy -- methods
- Recurrence
- Sex Factors
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
There are no comments on this title.
Log in to your account to post a comment.